Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) gapped down prior to trading on Wednesday after Cantor Fitzgerald downgraded the stock from an overweight rating to a neutral rating. The stock had previously closed at $15.10, but opened at $11.10. Cantor Fitzgerald now has a $10.00 price target on the stock, down from their previous price target of $21.00. Cytokinetics, shares last traded at $8.25, with a volume of 7446300 shares traded.

Several other research firms also recently weighed in on CYTK. Morgan Stanley reaffirmed an “overweight” rating and set a $25.00 price target (up previously from $24.00) on shares of Cytokinetics, in a research note on Friday, October 6th. Seaport Global Securities reaffirmed a “buy” rating and set a $24.00 price target on shares of Cytokinetics, in a research note on Friday, October 6th. HC Wainwright set a $26.00 price target on shares of Cytokinetics, and gave the company a “buy” rating in a research note on Thursday, August 3rd. ValuEngine raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, BidaskClub raised shares of Cytokinetics, from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $17.64.

In related news, insider Caryn Gordon Mcdowell sold 4,260 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $12.94, for a total transaction of $55,124.40. Following the completion of the transaction, the insider now directly owns 17,982 shares in the company, valued at $232,687.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Santo J. Costa sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $14.00, for a total transaction of $70,000.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $70,000. The disclosure for this sale can be found here. Insiders sold 178,223 shares of company stock worth $2,639,239 over the last ninety days. Corporate insiders own 7.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its position in Cytokinetics, by 456.1% during the second quarter. Goldman Sachs Group Inc. now owns 286,018 shares of the biopharmaceutical company’s stock valued at $3,461,000 after purchasing an additional 234,588 shares during the period. Prudential Financial Inc. acquired a new position in Cytokinetics, during the second quarter valued at $913,000. Swiss National Bank acquired a new position in Cytokinetics, during the second quarter valued at $697,000. Ameriprise Financial Inc. acquired a new position in Cytokinetics, during the second quarter valued at $2,914,000. Finally, Janus Henderson Group PLC acquired a new position in Cytokinetics, during the second quarter valued at $32,488,000. Institutional investors own 71.92% of the company’s stock.

The company has a debt-to-equity ratio of 0.14, a current ratio of 7.60 and a quick ratio of 7.60.

Cytokinetics, (NASDAQ:CYTK) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. The company had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. equities analysts anticipate that Cytokinetics, Incorporated will post -2.4 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/23/cytokinetics-incorporated-cytk-shares-gap-down-after-analyst-downgrade.html.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.